Crowd Funding Memorandum Download

DAMPS BIOMED I LP Crowd Funding Memorandum (CFM)

DAMPS.com Web Site Launch

Objective

General Partner (GP) Jeff Brown is engaging a new California Limited Partnership,

designated DAMPS BIOMED I LP, for continued branding of DAMPS TM technology
footwear in the medical and podiatric footwear markets. DAMPS advanced magnetic
shock mitigation technology will provide determinant prevention and treatment for
impact related lower extremity injury.


DAMPS I LP General Partner Jeff Brown is exclusively licensing specific DAMPS
Intellectual Property (IP) to DAMPS BIOMED I LP, in return for designated payback of
original DAMPS I LP investors and ongoing licensing royalties. DAMPS I LP will
continue to mature and market the military, commercial/professional work and sportsman
boot/shoe markets.



Funding

As designated with the 2012 Jobs Bill. DAMPS BIOMED I LP is raising one million

dollars in it’s first round. Additional funding phases will be designated for
manufacturing ramp up in accordance with proposed license agreements.



SEC Standards

While there are no Form D or accredited investor filing requirements associated with

Crowd Funding, DAMPS BIOMED I LP will be treating all investors in accordance with
comparable current Regulation D Rule 506 investor offerings, regarding risk, diligence
operations and revenue distributions. All investment money raised will be held in an
authorized holding account managed by the General Partner and Waterstone Capital.



Intellectual Property

DAMPS I LP currently holds the DAMPS TM Trademark, three patents, five registered
domain names, with assorted manfuacturing, marketing and material trade secrets. Six
new patents are in filing preparation.



Valuation

Current DAMPS Technology is valued at ten million dollars in the growing eleven billion
dollar boot market. DAMPS BIOMED I LP is also valued at ten million dollars and will
be reevaluated after each milestone and completed round of funding.

Projections

The plantar fascitiis treatment market is mature, in the billions and growing as baby
boomers get older and begin experiencing foot problems. The prevention side of the
market is also growing as social media and the internet educate us about our health
concerns and options.

Underwriting

Waterstone Capital LLC is our underwriting partner and is providing bridge funding to

support the management and marketing of this offering. Larry Hudson Managing Partner.
www.WaterstoneCapital.com



Background

With our military POC (Point of Contact) and contact administrator SAIC (Science

Applications International Corporation) here in San Diego, DAMPS Technology Smart
Boots have completed successfully Phase I contract user field and combat tested in 2010-
2012 with Special Operations SOF (Special Operation Forces), SORSE (Special
Operations Research Development, Test & Evaluation) and AFSOC (Air Force Special
Operations Command).


Our continued plan is to add 2013 Phase II contract award to include two hundred fifty
user ninety day, double blind field testing data to support DAMPS Technology as a
510(k) FDA medical device for the prevention and treatment of plantar fascitiis (heel
strike injury). Currently DAMPS is a 510(k) exempt medical device, as instructed by the
FDA allowing us to market the amount of shock mitigation but not the direct benefits.


DAMPS testing included F-Scan pressure surface testing and recorded over 68% increase
in heel strike shock mitigation when compared to conventional footwear. DAMPS has
also been independently third party accelerometer tested at 1G 3G and 5G load levels
with outstanding results in comparison with current shock reduction technology footwear.



Funding Deliverables

DAMPS BIOMED I LP will ramp up management, marketing and CNC machine a

minimum of nine (9) production molds and manufacture and assemble five hundred pairs
in three to four sizes of DAMPS Technology Outsoles and DAMPS Technology Inserts
(DTI), with varied working, walking, medical and athleisure uppers. The manufactured
footwear samples will be utilized to support 510(k) testing and to demonstrate DAMPS
Technology to designated medical license manfuacturing partners and trade shows.



DAMPS Management Statements



Dr. John A. Ciccone DPM

“At this point in time, I am addressing the potential marketing of the DAMPS system of

shock mitigation footwear. As the only tested and proven system to decelerate the impact
of heel strike and then assist the propulsive phase of gait, DAMPS is on the verge of
coming to market. The testing by the military and the results of independent
quantification of its efficacy will allow the marketing of the system to the military, the
public sector and also the growing segment of the population able to access shoes through
the federal Medicare system of DME (Durable Medical Equipment), where therapeutic
shoes are prescribed by physicians and podiatrists for eligible baby boomers. At this time
when the fifty five and above segment of the population is retiring but not giving up any

activities including high impact sports, i.e. running, tennis and softball, the incident of
injury us well into double digits.”


As the year progresses we are ready to come to market on the up slope of this trend in foot related problems and the need for this type of shoe.


Respectfully submitted.



Ed Stone President of Boot World

I like the idea of making footwear better and improving shock mitigation is an area of

great importance. There is no better technology to reduce shock mitigation then Damps
Technology and it does not wear out! Its performance can be relied on for the life of the
shoe or apparatus. This in itself is an amazing feat in this day of smoke and mirrors and
fad, “throw away gimmicks”.



Jon Nussbaum Military POC SAIC

“It is the right time for DAMPS in the US military. The shock mitigation properties which DAMPS uniquely provides has been needed by all branches of the military for over a decade, but is need now more than ever due to a spontaneously shrinking budget, an emerging smaller peace time professional all-volunteer force, with continued dependence on an older per capita Reserve and National Guard. The DAMPS boot is needed to protect recruits from lower extremity injuries (approximately 30% sustain these injuries during basic training), Line units which are carrying heavier and heavier combat and basic loads than ever before, and reserve forces which are getting older and more prone to injuries then the regular forces. The DAMPS boot, as tested by all branches of the military and special forces (Army, Navy/Marines, Air Force and US Special Forces Command, is the only identified solution to ease extensive shock experienced by dismounted troops/Marines, enhance the wearers tolerance and endurance while sustaining readiness and alertness. This product protects the force and reduces the life cycle cost of the soldier while maintain force readiness and preparedness.”



Bill Walton NBA Hall of Famer

“If your footwear doesn’t work for you, you are simply dragging around a logo. Please be smarter than your shoes. There’s a reason why I am a DAMPS I LP Investor.”



Founder General Partner Jeff Brown

“We are very excited to be able to offer the medical markets the benefits of a proven

shock mitigation technology. Our F-Scan pressure mapping testing and user field testing
with Special Operation Forces (SOF) along with independent third part 1G 3G & 5G
accelerometer testing, secure DAMPS as the leader in shock mitigation footwear for the
military, medical and commercial work/professional markets.”

 

Investment Participation

After sufficient time for qualified review, consideration and professional consultation,

interested individual investors may download the DAMPS I BIOMED Crowd Funding
Memorandum and Investment agreement from www.damps.com or
www.WaterstoneCapital.com.
Cashiers or Bank checks Payable to DAMPS BIOMED I LP.


Investment participation is available at four levels. (Percentage ownership is of 100%
Total Equity Available)


1) $1,000 equals .01% DAMPS I BIOMED LP equity ownership.
2) $2,500 equals .025% DAMPS BIOMED I LP equity ownership.
3) $5,000 equals .05% DAMPS I BIOMED I LP equity ownership.
4) $10,000 equals .10% DAMPS I BIOMED I LP equity ownership.
5) Offers over $ 10,000 for DAMPS I BIOMED I LP equity, please request the DAMPS Supplement I (DSI) ceo@damps.com.



Investor Payback

Investors will receive; 1) their equal percentage equity ownership as profits from net

revenues earned by the partnership. 2) Investors also receive free DAMPS Technology
footwear for themselves and immediate family for the life of the venture. 3) Management
will also offer a designated buy back of current round equity with second year round two
funding.


Federal and California K-1 tax filings will be sent to individual investors each year for
tax purposes. Individual Limited Partnership investors are responsible for their own tax
obligations.



Safe Harbor Statement

This information includes forward-looking statements covered by the Private Securities

Litigation Reform Act of 1995. Because such statements deal with future events, they are
subject to various risks and uncertainties and actual results for fiscal year 2013 and
beyond could differ materially from the Company's current expectations. Forwardlooking statements are identified by words such as "anticipates," "projects," "expects,"
"plans," "intends," "believes," "estimates," "targets," and other similar expressions that
indicate trends and future events.


Factors that could cause the Company's results to differ materially from those expressed
in forward-looking statements include, without limitation, variation in demand and
acceptance of the Company's products and services, the frequency, magnitude and timing of paper and other raw-material-price changes, general business and economic conditions

beyond the Company's control, timing of the completion and integration of acquisitions,
the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment
strategies, and the Company's success in attracting and retaining key personnel. The
Company undertakes no obligation to revise or update forward-looking statements as a
result of new information, since these statements may no longer be accurate or timely.